arXiv subjects

Kevin Horgan

Publications and source records attributed to Kevin Horgan.

2 recordsLinked to original sources

arXiv2026

Spaceflight KID Readout Electronics for PRIMA

We present the design and testing of a prototype multiplexing kinetic inductance detector (KID) readout electronics for the PRobe far-Infrared Mission for Astrophysics (PRIMA) space mission. PRIMA is a Probe-class astrophysics mission concept that will answer fundamental questions about the formation of planetary systems, the co-evolution of stars and supermassive black holes in galaxies, and the rise of heavy elements and dust over cosmic time. The readout electronics for PRIMA must be compatible with operation at Earth-Sun L2 and capable of multiplexing more than 1000 detectors over 2.5 GHz bandwidth while consuming around 30 W per readout chain. The electronics must also be capable of switching between the two instruments, which have different readout bands: the hyperspectral imager (PRIMAger, 2.6-4.9 GHz) and the spectrometer (FIRESS, 0.4-2.4 GHz). The PRIMA readout electronics use high-heritage SpaceCube digital electronics with a build-to-print SpaceCube Mini v3.0 board using a radiation-tolerant Kintex KU060 field programmable gate array (FPGA) and a custom high-speed digitizer board, along with RF electronics that provide filtering and power conditioning. We present the driving requirements for the system, as well as the hardware, firmware, software, and system-level design that meets those requirements.

astro-ph.IM↗

arXiv2020

Stable discovery of interpretable subgroups via calibration in causal studies

Building on Yu and Kumbier's PCS framework and for randomized experiments, we introduce a novel methodology for Stable Discovery of Interpretable Subgroups via Calibration (StaDISC), with large heterogeneous treatment effects. StaDISC was developed during our re-analysis of the 1999-2000 VIGOR study, an 8076 patient randomized controlled trial (RCT), that compared the risk of adverse events from a then newly approved drug, Rofecoxib (Vioxx), to that from an older drug Naproxen. Vioxx was found to, on average and in comparison to Naproxen, reduce the risk of gastrointestinal (GI) events but increase the risk of thrombotic cardiovascular (CVT) events. Applying StaDISC, we fit 18 popular conditional average treatment effect (CATE) estimators for both outcomes and use calibration to demonstrate their poor global performance. However, they are locally well-calibrated and stable, enabling the identification of patient groups with larger than (estimated) average treatment effects. In fact, StaDISC discovers three clinically interpretable subgroups each for the GI outcome (totaling 29.4% of the study size) and the CVT outcome (totaling 11.0%). Complementary analyses of the found subgroups using the 2001-2004 APPROVe study, a separate independently conducted RCT with 2587 patients, provides further supporting evidence for the promise of StaDISC.

stat.ME↗